IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

D'AMBROSIO, ROBERTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.259
NA - Nord America 4.646
AS - Asia 4.595
SA - Sud America 476
AF - Africa 122
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 10
Totale 15.136
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.424
GB - Regno Unito 1.922
CN - Cina 1.375
SG - Singapore 1.248
DE - Germania 821
IT - Italia 785
BD - Bangladesh 500
SE - Svezia 448
HK - Hong Kong 413
BR - Brasile 366
RU - Federazione Russa 341
VN - Vietnam 284
IN - India 218
FR - Francia 216
CA - Canada 152
FI - Finlandia 138
NL - Olanda 129
IE - Irlanda 124
UA - Ucraina 106
TR - Turchia 97
KR - Corea 96
DK - Danimarca 64
ID - Indonesia 61
JP - Giappone 60
EU - Europa 47
TW - Taiwan 45
CI - Costa d'Avorio 44
MX - Messico 39
IQ - Iraq 36
BE - Belgio 28
CO - Colombia 28
ES - Italia 27
ZA - Sudafrica 25
AU - Australia 24
CL - Cile 20
EG - Egitto 19
PL - Polonia 19
KH - Cambogia 18
UZ - Uzbekistan 18
AR - Argentina 17
PK - Pakistan 17
CH - Svizzera 16
PH - Filippine 16
EC - Ecuador 13
CR - Costa Rica 12
GR - Grecia 12
TH - Thailandia 12
VE - Venezuela 11
AT - Austria 10
MY - Malesia 10
IL - Israele 9
IR - Iran 9
PT - Portogallo 9
SA - Arabia Saudita 9
UG - Uganda 9
JO - Giordania 8
MA - Marocco 8
RO - Romania 8
PE - Perù 7
PY - Paraguay 7
AE - Emirati Arabi Uniti 6
AZ - Azerbaigian 5
JM - Giamaica 5
MM - Myanmar 5
NO - Norvegia 5
PA - Panama 5
PS - Palestinian Territory 5
SI - Slovenia 5
NP - Nepal 4
NZ - Nuova Zelanda 4
BG - Bulgaria 3
BO - Bolivia 3
ET - Etiopia 3
HN - Honduras 3
HU - Ungheria 3
NG - Nigeria 3
UY - Uruguay 3
CZ - Repubblica Ceca 2
DZ - Algeria 2
IS - Islanda 2
KE - Kenya 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LT - Lituania 2
LU - Lussemburgo 2
LV - Lettonia 2
MD - Moldavia 2
MQ - Martinica 2
PR - Porto Rico 2
SK - Slovacchia (Repubblica Slovacca) 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AD - Andorra 1
AL - Albania 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CD - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
DO - Repubblica Dominicana 1
Totale 15.161
Salva come PNG Salva come JPEG
Città #
Southend 1.765
Singapore 699
Ashburn 517
Hong Kong 361
Chandler 330
San Jose 288
Beijing 277
Milan 253
Dallas 206
Seattle 177
Princeton 138
Los Angeles 135
New York 134
Santa Clara 134
Wilmington 134
Council Bluffs 133
Dublin 122
Hanover 122
Fairfield 118
Frankfurt am Main 105
Ho Chi Minh City 100
Ann Arbor 98
Dearborn 97
Houston 87
Toronto 85
Woodbridge 81
Nanjing 78
Guangzhou 75
Buffalo 74
Helsinki 73
Lauterbourg 72
Hanoi 68
Bengaluru 67
Boardman 63
Hefei 58
Jacksonville 58
Des Moines 57
Moscow 57
Mountain View 52
Munich 51
Cambridge 50
Andover 46
Columbus 45
Redmond 45
Abidjan 44
Rome 43
Shanghai 42
Jakarta 33
Phoenix 32
Jinan 31
The Dalles 31
Shenyang 28
Serra 26
Tokyo 26
Berlin 25
Piscataway 25
São Paulo 25
Tianjin 25
Brussels 24
Kent 24
Changsha 23
Hebei 23
Sakarya 23
Cangzhou 22
Naples 22
San Diego 22
Turin 22
Montreal 21
Seoul 21
Bogotá 20
Hangzhou 20
Saint Petersburg 20
Taichung 20
Jiaxing 19
Istanbul 18
Nuremberg 18
Ottawa 18
Phnom Penh 18
Somerville 18
Atlanta 17
Baghdad 16
Chicago 15
Mumbai 15
Redwood City 15
Zhengzhou 15
Da Nang 14
Nanchang 14
Florence 13
Haiphong 13
Turku 13
Bologna 12
Johannesburg 12
London 12
Warsaw 12
Washington 12
Wuhan 12
Athens 11
Bitonto 11
Brooklyn 11
Cairo 11
Totale 8.933
Salva come PNG Salva come JPEG
Nome #
Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs 630
Prevalence of psychiatric disorders during PEG – Interferon and Ribavirin therapy in patients with chronic hepatitis HCV-correlated 397
The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent 351
Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C 317
The international autoimmune hepatitis group scoring system in patients with chronic hepatitis C and serum autoantibodies undergoing interferon/ribavirin therapy : a prospective validation study 297
The relationship between liver histology and thyroid function tests in patients with nonalcoholic fatty liver disease (NAFLD) 292
Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon 275
Hepatitis C virus deletion mutants are found in individuals chronically infected with genotype 1 hepatitis c virus in association with age, high viral load and liver inflammatory activity 269
Evaluation of three “beyond Baveno VI” criteria to safely spare endoscopies in compensated advanced chronic liver disease 262
Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving telaprevir 256
Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C 249
Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis 247
The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia 245
The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy 242
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C 234
A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms 230
Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B 228
Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients 224
Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4 223
Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy 222
The natural history of portal hypertension in patients with HCV related compensated cirrhosis undergoing interferon ribavirin therapy 220
Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study 220
Ribavirin impairs salivary gland function in hepatitis C patients during combination treatment with pegylated interferon alfa-2a 218
A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis : the interferon-inducible gene IFI16 217
Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients : a single-centre study 210
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting 210
The influence of liver fibrosis on the outcome of pegylated interferon and ribavirin anti-hac therapy : a sub-analysis of the mist study 209
The diagnostic accuracy of fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with an SVR 207
The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype 206
12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis 206
Rare ATG7 genetic variants predispose patients to severe fatty liver disease 203
Randomized Study of Peginterferon-alpha2a Plus Ribavirin vs Peginterferon-alpha2b Plus Ribavirin in Chronic Hepatitis C 201
A morphometric and immunohistochemical study to assess the benefit of an svr in hcv cirrhotic patients 201
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis 199
Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3α hepatitis C virus infection 193
Hepatocellular carcinoma in patients with a sustained response to anti-hepatitis C therapy 191
A territory-wide opportunistic, hospital-based HCV screening in the general population from northern Italy: The 1969-1989 birth-cohort 190
A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C 189
Acute tubular necrosis following interferon-based therapy for hepatitis C : case study with literature review 186
Interferoni pegilati nel trattamento dei pazienti con epatite cronica HCV : esperienze a confronti 182
Decompensation in Direct-Acting Antiviral Cured Hepatitis C Virus Compensated Patients With Clinically Significant Portal Hypertension: Too Rare to Warrant Universal Β-Blocker Therapy 180
Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression 179
Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C 178
Standard and pegylated interferon alfa-2b plus ribavirin as initial treatment for HCV genotype 2 chronic hepatitis : analysis of a large single center cohort 177
Optimizing treatment with pegylated interferon-ribavirin of genotype 3 chronic hepatitis C : more questions than answers 175
Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis 174
Clinical and genetic determinants of the fatty liver–coagulation balance interplay in individuals with metabolic dysfunction 173
Low rates of sustained virological response to interferon and ribavirin therapy in genotype 3 infected patients with compensated cirrhosis 166
Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis 166
Lack of alanine aminotransferase normalization in patients with an anti-hcv virological response during pegylated interferon and ribavirin therapy : a sub-analysis of the mist study 164
Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from Italy 164
Impact of HCV and Direct Acting Antivirals on Kidney Recipients: a retrospective study 162
HCV-RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin 156
Prevalence of HCV infection in Europe in the DAA era: Review 149
Hepatocellular carcinoma in patients with compensated HCV-related cirrhosis responding to interferon : A 5-year follow-up study 149
De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis c (case study and literature review) 149
Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis 148
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores 144
Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: Case study 141
The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response 138
Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease 137
Effectiveness and safety of sofosbuvir-based direct-acting antiviral combinations in HCV-2 and HCV-3 kidney transplant recipients 135
Transient elastography to assess liver fibrosis in patients with sickle cell disease 133
Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19 133
Pegylated interferons and ribavirin therapy for the treatment of chronic hepatitis C in thalassaemia major patients : preliminary results 129
Treatment of experienced and naïve patients with hepatitis C : focus on telaprevir 129
Liver damage and sickle cell disease: genotype relationship 128
Treatment of patients with HCV related cirrhosis : many rewards with very few risks 127
Development and Validation of a PIVKA-II-Based Model for HCC Risk Stratification in Patients With HCV-Related Cirrhosis Successfully Treated With DAA 124
Treatment of non-alcoholic steatosis : Preclinical study of a new nutraceutical multitarget formulation 120
Editorial : good news to patients with thalassaemia €”HCV clearance made easy with direct-acting antivirals 119
Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure 118
Treating hepatitis C in patients with hemoglobinopathies 117
Safety of Sofosbuvir-Based Direct-Acting Antivirals for Hepatitis C Virus Infection and Direct Oral Anticoagulant Co-Administration 116
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 112
Clinical exome sequencing for diagnosing severe cryptogenic liver disease in adults: A case series 106
Safety of direct antiviral agents in real life 102
Editorial: the role for PIVKA-II measurement after HCV elimination by direct-acting antivirals in terms of prediction of hepatocellular carcinoma—authors' reply 96
A new clinical and prognostic characterization of the patterns of decompensation of cirrhosis 95
Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies 88
Proteomics to predict hepatitis C therapy outcome : where do we stand? 80
Correction: Micheli et al. Treatment of Non-Alcoholic Steatosis: Preclinical Study of a New Nutraceutical Multitarget Formulation. Nutrients 2020, 12, 1819 71
Is it time to refine HCC surveillance strategies in HCV cured patients? 68
Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B 63
Diagnostic Accuracy of Non-Invasive Tests for MASLD Across Age, Type 2 Diabetes, and Obesity Subgroups: A Multinational Study 55
Impact of first and further decompensation in patients with compensated ACLD due to MASLD 43
Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study 32
Impact of Hepatocellular Carcinoma on the risk of liver decompensation: a comparative analysis of patients with and without HCC: Role of HCC in liver decompensation 19
null 19
Unmet needs in hepatology: The guidance of the Italian association for the study of the liver (AISF) 18
Hepatitis C eradication improves oncologic and clinical outcomes in patients treated with Atezolizumab plus Bevacizumab 13
Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection 7
null 1
Totale 15.833
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.240
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.240
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021115 0 0 0 0 0 0 0 0 0 0 0 115
2021/20221.121 84 61 34 86 129 97 95 74 125 105 66 165
2022/20231.180 142 143 111 138 116 207 17 77 127 23 59 20
2023/2024807 47 66 30 54 222 65 34 39 49 36 68 97
2024/20252.168 67 235 34 214 188 97 90 177 102 225 246 493
2025/20265.499 538 316 517 358 420 338 648 254 484 382 788 456
Totale 15.833